CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or
refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.